Diamond Member Pelican Press 0 Posted July 20, 2025 Diamond Member Share Posted July 20, 2025 Shares of Sarepta Therapeutics experienced a sharp decline today following a cautious statement from the Food and Drug Administration (FDA) regarding the company’s gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). The FDA’s update, released late yesterday, tempered earlier enthusiasm surrounding the drug’s potential efficacy, sending shockwaves through the investment community and… This is the hidden content, please Sign In or Sign Up This is the hidden content, please Sign In or Sign Up 0 Quote Link to comment https://hopzone.eu/forums/topic/281822-sarepta-stock-plummets-after-fda-elevidys-update/ Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.